The identification of specific genetic mutations associated with certain types of malformations and lesions, such as PIK3CA mutations in lymphatic malformations and GNA14 mutations in Kaposiform Haemangioendothelioma, has opened doors for targeted therapies using pathway inhibitors [2,9]. This evidence concerns the gene GNA14 and lymphatic malformation.